YDR239C Antibody

What is YDR239C and why is it relevant to neurodegenerative disease research?

YDR239C is a yeast gene that has emerged as an important model for studying neurodegenerative disorders, particularly tauopathies including Alzheimer's disease. This gene was identified during tau toxicity enhancer screening using yeast deletion collections, with significant implications for understanding tau pathology mechanisms . The methodological approach involves using humanized yeast models expressing tau protein to identify genetic modifiers that enhance tau-mediated toxicity. YDR239C strain (YKO_0823 H06) showed a robust positive interaction score of 0.972 in tau toxicity screens, making antibodies against its protein product valuable tools for investigating tau-related pathways .

How are YDR239C antibodies used in basic yeast model systems?

YDR239C antibodies are primarily employed for protein detection in yeast models engineered to express human tau protein. The methodological workflow typically involves:

• Transformation of yeast with plasmids expressing human tau40

• Protein extraction and fractionation (often using Sarkosyl fractionation)

• Western blot analysis using YDR239C antibodies to detect the protein

• Immunofluorescence microscopy to visualize protein localization and inclusion formation

This approach enables researchers to track YDR239C protein levels and localization in relation to tau expression and aggregation. For optimal results, antibody dilutions of 1:500 are commonly used, similar to other protein-specific antibodies in yeast-based neurodegeneration models .

What experimental controls should be included when using YDR239C antibodies?

Proper experimental design for YDR239C antibody applications requires multiple controls:

Researchers should additionally perform appropriate blocking steps and titrate antibody concentrations to optimize signal-to-noise ratios in immunoblotting and immunofluorescence applications .

How can YDR239C antibodies be utilized to study tau-Aβ interactions in yeast models?

YDR239C antibodies provide sophisticated tools for investigating tau-Aβ interactions in yeast models. Advanced research methodologies include:

• Co-immunoprecipitation assays using YDR239C antibodies to pull down protein complexes containing both YDR239C and tau/Aβ proteins

• Proximity ligation assays to visualize potential interactions between YDR239C, tau, and Aβ in situ

• Fluorescence resonance energy transfer (FRET) between labeled YDR239C antibodies and tau/Aβ antibodies to measure protein-protein proximity

Recent research indicates that tau and Aβ co-localize in yeast models, with Aβ1-42 potentially involved in tau40 phosphorylation via GSK-3β yeast orthologues, while tau appears to facilitate Aβ1-42 oligomerization . YDR239C antibodies can help elucidate whether this gene product participates in these pathological processes by identifying subcellular localization patterns and protein interaction networks.

What advanced techniques leverage YDR239C antibodies for high-throughput drug discovery?

YDR239C antibodies enable sophisticated drug discovery methodologies, particularly in the context of systems like GPSD2™ developed for tauopathy therapeutics. Implementation involves:

• Development of automated immunofluorescence workflows using YDR239C antibodies to quantify protein expression in response to compound treatment

• Integration with high-content imaging platforms for multiparametric phenotypic analysis

• Establishment of ELISA-based screening systems for quantitative measurement of YDR239C protein levels

The mir1Δ-tau40 yeast strain has demonstrated particular utility in drug discovery screening systems, with three extracts from marine bacteria obtained from Mid-Atlantic Ridge hydrothermal vents identified as tau toxicity suppressors . These methodological approaches provide frameworks for identifying novel therapeutic compounds that may modulate YDR239C-related pathways in tauopathies.

How can researchers optimize YDR239C antibody-based immunoprecipitation for identifying novel protein interactions?

Optimizing YDR239C antibody-based immunoprecipitation requires careful consideration of multiple methodological parameters:

• Cross-linking optimization: Titrate formaldehyde or DSS concentrations (0.1-3%) to preserve transient interactions

• Lysis buffer composition: Test different detergent combinations (CHAPS, NP-40, Triton X-100) at varying concentrations to maximize protein extraction while preserving interactions

• Antibody coupling: Compare direct coupling to magnetic beads versus indirect capture using protein A/G

• Elution strategies: Evaluate competitive elution with peptides versus pH-based elution for highest yield and specificity

Researchers should consider sequential immunoprecipitation approaches to identify specific subcomplexes, particularly when investigating YDR239C interactions with tau aggregates under different phosphorylation states. Mass spectrometry analysis of immunoprecipitated complexes can reveal novel interaction partners within the tau interactome framework identified through genomic screens .

What are the optimal fixation and permeabilization protocols for YDR239C antibody immunocytochemistry in yeast models?

Successful immunocytochemistry using YDR239C antibodies in yeast models requires careful optimization of fixation and permeabilization protocols:

For co-localization studies with tau aggregates, researchers should consider implementing a sequential staining protocol, performing YDR239C antibody staining first, followed by tau antibodies, to minimize potential epitope masking effects. Fluorescence microscopy analysis should incorporate counting methods to quantify cells with protein inclusions for statistical evaluation .

How should researchers troubleshoot weak or non-specific YDR239C antibody signals in Western blots?

Addressing weak or non-specific YDR239C antibody signals requires systematic troubleshooting:

• Sample Preparation:

  • Implement Sarkosyl fractionation to separate soluble and insoluble protein fractions

  • Add protease and phosphatase inhibitors immediately upon cell lysis

  • Optimize protein extraction from yeast cells through multiple freeze-thaw cycles

• Antibody Conditions:

  • Test multiple antibody concentrations (1:250 to 1:1000 dilutions)

  • Extend primary antibody incubation time (overnight at 4°C)

  • Evaluate different blocking agents (milk vs. BSA) for reduced background

• Detection Method:

  • Compare chemiluminescence vs. fluorescence-based detection systems

  • Consider signal amplification systems for low-abundance proteins

  • Implement longer exposure times with lower antibody concentrations

When analyzing tau-YDR239C interactions, researchers should consider the potential impact of tau-induced changes in YDR239C expression or localization, which may require adjustment of standard protocols .

What considerations are important when using YDR239C antibodies in human cell models?

Translating YDR239C antibody applications from yeast to human cell models requires addressing several methodological considerations:

• Target conservation analysis: Identify the human homologue (such as SLC25A3 for MIR1) and verify epitope conservation

• Antibody cross-reactivity validation: Confirm specific binding to human homologues through Western blot and immunoprecipitation

• Background reduction: Implement extensive blocking and washing steps to minimize non-specific binding in complex human cellular matrices

• Cell type-specific protocols: Optimize conditions for neuronal cells (such as H4 neuroglial cells) versus non-neuronal cell types

Researchers should consider RNA interference approaches to silence the human homologue expression in neuronal cells as a validation strategy for antibody specificity. This approach has been successfully implemented with SLC25A3, the human homologue of MIR1, in human neuroglioma cells to develop neural models that replicate yeast findings .

How should researchers quantify and normalize YDR239C antibody signals in comparative studies?

Robust quantification and normalization of YDR239C antibody signals requires comprehensive analytical approaches:

• Densitometric analysis: Utilize digital image analysis software with linear dynamic range for Western blot quantification

• Multi-reference normalization: Employ multiple housekeeping proteins (PGK-1, GAPDH, β-actin) for more reliable normalization across experimental conditions

• Replicate design: Incorporate biological triplicates and technical duplicates for statistical robustness

• Standardization curves: Generate standard curves using recombinant protein to establish absolute quantification

For fluorescence microscopy data, researchers should implement automated image analysis workflows to quantify parameters such as signal intensity, subcellular distribution, and co-localization coefficients with tau aggregates. Statistical analysis should employ appropriate tests based on data distribution and experimental design .

What approaches can resolve contradictory findings when using different YDR239C antibody clones?

Addressing contradictory results from different YDR239C antibody clones requires systematic investigation:

• Epitope mapping: Determine the specific regions recognized by each antibody clone

• Post-translational modification sensitivity: Assess whether phosphorylation or other modifications affect epitope recognition

• Validation through orthogonal methods: Confirm findings using genetic approaches (RNAi, CRISPR) to manipulate target levels

• Cross-reactivity profiling: Evaluate potential cross-reactivity with related proteins through immunoprecipitation followed by mass spectrometry

When comparing data across studies, researchers should critically evaluate the specific antibody clones used and their validation methods. Collaborative validation across multiple laboratories can help establish consensus regarding contradictory findings and determine which antibody clones provide the most reliable results for specific applications.

How can YDR239C antibody data be integrated with genomic screening results to identify novel tau toxicity mechanisms?

Integrating YDR239C antibody data with genomic screening results requires sophisticated multi-omics approaches:

• Correlation analysis: Map protein expression/localization patterns against genomic screen hits

• Network biology: Construct protein-protein interaction networks connecting YDR239C with tau toxicity modifiers

• Functional enrichment: Identify biological pathways overrepresented among interacting partners

• Comparative interactomics: Analyze conservation of interactions between yeast and human cellular models

The tau interactome framework derived from genomic screens, comprising 31 genes identified as tau toxicity enhancers, provides valuable context for interpreting YDR239C antibody data . Researchers should prioritize investigation of potential functional connections between YDR239C and mitochondrial phosphate carrier protein (PiC), given the established relationship between tau pathology and mitochondrial function revealed through the mir1Δ yeast strain's sensitivity to tau toxicity .

How can YDR239C antibodies support validation of compounds identified in primary screens?

YDR239C antibodies provide crucial secondary validation tools for potential therapeutic compounds:

• Target engagement verification: Confirm whether compounds directly interact with or modify YDR239C through cellular thermal shift assays (CETSA) with antibody detection

• Mechanistic classification: Categorize compounds based on their effects on YDR239C expression, localization, and post-translational modifications

• Selectivity profiling: Assess compound effects on related proteins using antibody panels

• Pharmacodynamic monitoring: Track YDR239C-related biomarkers during dose-response and time-course studies

This methodological approach has proven valuable in validating the three marine bacteria extracts identified as tau toxicity suppressors in the mir1Δ-tau40 yeast model . Researchers should implement multiplexed antibody-based assays to simultaneously monitor effects on YDR239C and key tau pathology markers.

What antibody-based screening methods can identify compounds that modify YDR239C-tau interactions?

Advanced antibody-based screening approaches can identify compounds that specifically modulate YDR239C-tau interactions:

• AlphaScreen/AlphaLISA: Develop homogeneous assays using antibody pairs against YDR239C and tau to detect proximity in solution

• Split-reporter complementation: Create YDR239C-antibody and tau-antibody conjugates linked to complementary reporter fragments

• Time-resolved FRET: Implement TR-FRET assays with lanthanide-labeled antibodies for improved signal-to-noise ratio

• Biolayer interferometry: Measure direct binding kinetics between immobilized antibody-captured YDR239C and tau protein

These methodological approaches can be adapted to high-throughput formats for screening chemical libraries or natural product extracts, such as those from marine bacteria obtained from Mid-Atlantic Ridge hydrothermal vents . Researchers should optimize assay conditions to detect both inhibitors and enhancers of protein interactions.

How can YDR239C antibody studies in yeast inform human neuronal models of tauopathies?

Translating findings from YDR239C antibody studies in yeast to human neuronal models requires methodological bridges:

• Homologue identification and validation: Confirm functional conservation between YDR239C and human counterparts (e.g., SLC25A3 as the human homologue of MIR1)

• Parallel model development: Establish complementary yeast and neuronal cell systems expressing the same tau variants

• Phenotypic correlation: Map tau-induced toxicity manifestations across model systems

• Intervention conservation: Test whether compounds effective in yeast show similar efficacy in neuronal models

Research using RNA interference to silence SLC25A3 expression in human neuroglioma cells represents a promising approach to replicating yeast findings in neural models . This translation is essential for understanding tau toxicity mechanisms at the mitochondrial level and validating potential drug targets identified in yeast screening systems.

What methodological considerations apply when using YDR239C antibodies in patient-derived samples?

Applying YDR239C antibody-based methods to patient-derived samples requires special considerations:

• Sample preservation protocols: Optimize fixation and processing methods to maintain epitope integrity in post-mortem or biopsy tissues

• Background reduction strategies: Implement autofluorescence quenching and endogenous peroxidase blocking for immunohistochemistry

• Cross-reactivity assessment: Validate antibody specificity against human homologues in the context of complex human tissue samples

• Reference range establishment: Develop standardized quantification methods with defined normal reference ranges

When examining potential associations between YDR239C homologues and tau pathology in patient samples, researchers should implement multiparametric analysis approaches to correlate antibody-detected protein levels with clinical parameters and other biomarkers of neurodegeneration.

How can antibody engineering approaches enhance YDR239C detection specificity and sensitivity?

Emerging antibody engineering technologies offer opportunities to improve YDR239C detection:

• Single-domain antibodies (nanobodies): Develop smaller antibody formats with enhanced tissue penetration

• Bispecific antibodies: Create reagents that simultaneously recognize YDR239C and tau for co-localization studies

• Recombinant antibody fragments: Engineer high-affinity scFv or Fab fragments with reduced non-specific binding

• Synthetic antibody libraries: Apply linear programming with inverse folding and protein language models to design optimized antibodies

Recent advances in antibody library design combining deep learning and multi-objective linear programming with diversity constraints provide powerful frameworks for developing next-generation YDR239C antibodies . These approaches leverage sequence and structure-based deep learning to predict mutation effects on antibody properties, which are then used to seed cascaded constrained integer linear programming problems to generate diverse, high-performing antibody libraries .

What role can YDR239C antibodies play in developing biomarkers for tauopathies?

YDR239C antibodies offer potential applications in biomarker development through several methodological approaches:

• Multiplex antibody arrays: Develop panels including YDR239C homologue antibodies alongside established tau pathology markers

• Ultrasensitive detection platforms: Implement single molecule array (Simoa) or immuno-PCR technologies for detecting low-abundance proteins in biological fluids

• Antibody-based proximity assays: Develop assays to detect specific protein-protein interactions as disease signatures

• Exosome immunocapture: Use antibodies to isolate neuronal exosomes containing YDR239C homologues as potential biomarkers

The identification of the relationship between tau pathology and mitochondrial function through the mir1Δ strain's sensitivity to tau toxicity suggests that mitochondrial phosphate carrier protein (PiC) and related proteins could serve as novel biomarkers for tau-related disorders . These biomarkers could potentially facilitate earlier diagnosis and treatment monitoring in neurodegenerative diseases with high human and socioeconomic impact.